CTIS2023-508229-28-00进行中(未招募)1 期
High-Intensity Inpatient MDMA-Assisted Psychotherapy for Treatment-Refractory Posttraumatic Stress Disorder: An Open-Label Pilot Study
Arq National Psychotrauma Centre0 个研究点目标入组 20 人开始时间: 2024年1月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64(—)
- 性别
- All
入选标准
- •Are at least 18 years, at the time of signing the informed consent., At Screening meet DSM-5 criteria for current PTSD with a symptom duration of at least 6 months., At Screening, have a PCL-5 score of 40 or greater (i.e., moderate to severe PTSD)., At screening, meet criteria for treatment-refractory PTSD, defined as having had at least two evidence-based trauma focused psychotherapies of at least 10 sessions per therapy.
排除标准
- •Have a current Personality Disorder, Have a diagnosis of uncontrolled hypertension, defined as repeated blood pressure readings of =140 mmHg systolic or =90 mmHg diastolic., Have a current eating disorder with compensatory behaviors, Have current major depressive disorder with psychotic features., Have a history of, or a current primary psychotic disorder or bipolar affective disorder type 1, Have a current moderate (not in early remission in the 3 months prior to enrollment and meets at least 5 of 11 diagnostic criteria per DSM-5) or severe alcohol or cannabis use disorder within the 12 months prior to enrollment (meets at least 6 of 11 diagnostic criteria per DSM-5)., Have an active illicit drug (other than cannabis) or prescription drug substance use disorder at any severity within 12 months prior to enrollment., Any participant presenting current serious suicide risk, as determined through psychiatric interview, responses to C-SSRS, and clinical judgment of the investigator will be excluded; however, history of suicide attempts is not an exclusion., Have a marked baseline QTcF interval >450 ms demonstrated on repeated ECG assessments., Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, heart failure, severe coronary artery disease, or aneurysm.
研究者
相似试验
已完成
不适用
Intensiv psychiatric-psychotherapeutic treatment for drug abusing patients during Opioid Substitution therapyF11.2F60.31F60.30F60.2F33.2F90.9Dissocial personality disorderRecurrent depressive disorder, current episode severe without psychotic symptomsHyperkinetic disorder, unspecifiedDRKS00015205Zentralinstitut für seelische Gesundheit Mannheim118
已完成
2 期
Methamphetamine associated psychosis and treatment with risperidone and halopridolMethamphetamine-associated psychosis.Mental and behavioural disorders due to use of other stimulants, including caffeineIRCT201507155280N19Vice chancellor for research of University of Social Welfare and Rehabilitation Sciences44
已完成
4 期
Prescribing pattern of psychotropic drugsCTRI/2018/04/013364DrDYPatil Medical CollegeNerul Navi mumbai426
招募中
2 期
Developing Optimal Psychedelic Assisted Psychotherapy for Obsessive-Compulsive DisorderTreatment Resistant Obsessive-Compulsive DisorderMental Health - Other mental health disordersACTRN12622001525774Australian National University40
招募中
不适用
Psychosocial Treatment for Methamphetamine Use Disorders in South Africa: A Pilot Study of a Cognitive Behavioural Therapy ProgramMethamphetamine Use DisordersPACTR20131000058929560
